CXCR4 antagonists for the treatment of HIV infection

Details CXCR4 antagonists for the treatment of HIV infection CXCR4 antagonists for the treatment of HIV infection

2011-08-30

2011-08-30

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S330000, C544S331000, C544S332000, C544S242000, 54, C514S332000

Reexamination Certificate

active

08008312

ABSTRACT:
The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor, and in particular to inhibit viral entry of certain viruses. Certain compounds in particular can reduce entry of immunodeficiency virus (HIV) into a cell while not reducing the capacity of stem cells to proliferate, and therefore can be useful for long term treatment regimes. The compounds are useful in particular in the treatment or prevention of HIV infections.

REFERENCES:
patent: 5874438 (1999-02-01), Schohe-Loop et al.
patent: 5993817 (1999-11-01), Yoneda et al.
patent: 6344545 (2002-02-01), Allaway et al.
patent: 6358915 (2002-03-01), Patierno et al.
patent: 6420354 (2002-07-01), Marquess et al.
patent: 6429308 (2002-08-01), Iijima et al.
patent: 6433149 (2002-08-01), Blaschuk et al.
patent: 6475488 (2002-11-01), Pasqualini et al.
patent: 6534626 (2003-03-01), Oravecz et al.
patent: 6750348 (2004-06-01), Bridger et al.
patent: 2004/0132642 (2004-07-01), Hwang
patent: 2004/0254221 (2004-12-01), Yamamazi et al.
patent: 2007/0054930 (2007-03-01), Shim et al.
patent: 2008/0227799 (2008-09-01), Liotta et al.
patent: 2009/0099194 (2009-04-01), Liotta et al.
patent: 515684 (1992-12-01), None
patent: WO 91/11994 (1991-08-01), None
patent: WO 97/00956 (1997-01-01), None
patent: WO 99/47158 (1999-09-01), None
patent: 99-63984 (1999-12-01), None
patent: WO 00/56729 (2000-09-01), None
patent: WO 01/38352 (2001-05-01), None
patent: WO 01/56591 (2001-08-01), None
patent: 01-70727 (2001-09-01), None
patent: WO 01/85196 (2001-11-01), None
patent: 02-02516 (2002-01-01), None
patent: WO 02/02516 (2002-01-01), None
patent: WO 02/094261 (2002-11-01), None
patent: WO 03/029218 (2003-04-01), None
patent: WO 2004/020462 (2004-03-01), None
patent: WO 2004/024178 (2004-03-01), None
patent: WO 2004/093817 (2004-04-01), None
patent: WO 2004/059285 (2004-07-01), None
patent: WO 2004/087068 (2004-10-01), None
patent: WO 2004/091518 (2004-10-01), None
patent: WO 2004/106493 (2004-12-01), None
patent: 2005-049607 (2005-06-01), None
patent: WO 2005/049607 (2005-06-01), None
patent: 2005-085189 (2005-09-01), None
STIC—search—Apr. 2009.
Wolff, Manfred E., Burgers Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, 975.
Banker, Gilbert S. et al., Modem Pharmaceutics, Marcel Dekker, New York, 1996.
Reyes et al. (Tetrahedron (2002), 58(42), 8573-8579).
Abdel-Magid, A.F., et al., “Reductive Amination of Aldehydes and Ketones with Sodium Triace-toxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1),”J. Org. Chem. 61(11):3849-3862 (May 31, 1996).
Abi-Younes, S., et al., “The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques,”Circ. Res., 86(2), 131-138 (Feb. 4, 2000)).
Alkhatib, G., et al., “CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1,”Science, 272(5270):1955-1958 (Jun. 28, 1996).
Blades, M.C., et al., “Stromal cell-derived factor 1 (CXCL12) induces human cell migration into human lymph nodes transplanted into SCID mice,”J. Immunol. 168(9):4308-4317 (May 1, 2002).
Bleul, C.C., et al., “The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry,”Nature, 382(6594):829-833 (Aug. 29, 1996).
Braun, C.E., et al., “Guanidine structure and hypoglycemia: some carbocyclic diguanidines,”J. Org. Chem., 3(2):146-152 (1938).
Bressler, N.M., and Bressler, S.B., “Preventative ophthalmology. Age-related macular degeneration,”Ophthalmology, 102(8):1206-1211 (Aug. 1995).
Butcher, E.C., et al. “Lymphocyte trafficking and regional immunity,”Adv. Immunol., 72:209-253 (1999).
Campbell, J.J., and Butcher, E.C., “Chemokines in tissue-specific and microenvironment-specific lymphocyte homing,”Curr. Opin. Immunol., 12(3):336-341 (Jun. 2000).
Chen, W.J., et al. “Recombinant human CXC-chemokine receptor-4 in melanophores are linked to Gi protein: seven transmembrane coreceptors for human immunodeficiency virus entry into cells,”Mol. Pharmacol., 53(2):177-181 (Feb. 1998).
Connor, R.I., et al., “Change in coreceptor use correlates with disease progression in HIV-1-infected individuals,”J. Exp. Med., 185(4):621-628 (Feb. 17, 1997).
Crane, I.J., et al., “CXCR4 receptor expression on human retinal pigment epithelial cells from the blood-retina barrier leads to chemokine secretion and migration in response to stromal cell-derived factor 1 alpha,”J. Immunol., 165(8):4372-4378 (Oct. 15, 2000).
Davis, C.B., et al. “Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5,”J. Exp. Med., 186(10):1793-1798 (Nov. 17, 1997).
Deng, H.K., et al., “Expression cloning of new receptors used by simian and human immunodeficiency viruses,”Nature, 388(6639):296-300 (Jul. 17, 1997).
Donzella, G.A., et al., “AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor,”Nat. Med., 4(1):72-77 (Jan. 1998).
Doranz, B.J., et al., “A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors,”Cell, 85(7):1149-1158 (Jun. 28, 1996).
Dwinell, M.B., et al., “Chemokine receptor expression by human intestinal epithelial cells,”Gastroenterology, 117(2):359-367 (Aug. 1999).
Eitner, F., et al., “Chemokine receptor (CXCR4) mRNA-expressing leukocytes are increased in human renal allograft rejection,”Transplantation, 66(11):1551-1557 (Dec. 15, 1998).
Feng, Y, et al., “HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor,”Science, 272(5263):872-877 (May 10, 1996).
Förster, R., et al., “CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs,”Cell, 99(1):23-33 (Oct. 1, 1999).
Fujii, N., et al., “The therapeutic potential of CXCR4 antagonists in the treatment of HIV,”Expert Opin. Investig. Drugs, 12(2):185-195 (Feb. 2003).
Gonzalo, J.A., et al., “Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease,”J. Immunol., 165(1),499-508 (Jul. 1, 2000).
Grove, G., “Epidermal cell kinetics in psoriasis,”Int. J. Dermatol., 18(2):111-122 (Mar. 1979).
Gupta, S.K., et al., “Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines,”J. Biol. Chem., 273(7):4282-4287 (Feb. 13, 1998).
Harris, E. D., Jr., “Rheumatoid arthritis. Pathophysiology and implications for therapy,”N. Eng. J. Med., 322(18):1277-1289 (May 3, 1990).
Hatse, S., et al., “Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4,”FEBS Lett527(1-3):255-262 (Sep. 11, 2002).
Hendrix, C.W., et al., “Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection,”J. Acquir. Immune Defic. Syndr., 37(2):1253-1262 (Oct. 1, 2004).
Homey, B., et al., “Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC),”J. Immunol., 164(7):3465-3470 (Apr. 1, 2000).
Kang, Y., et al., “A multigenic program mediating breast cancer metastasis to bone,”Cancer Cell, 3(6):537-549 (Jun. 2003).
Kijowski, J., et al., “The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells,”Stem Cells19(5):453-466 (2001).
Linton, B.R., et al., “Thermodynamic aspects of dicarboxylate recognition by simple artificial receptors

Affiliated with

Also associated with

Rating

CXCR4 antagonists for the treatment of HIV infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CXCR4 antagonists for the treatment of HIV infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CXCR4 antagonists for the treatment of HIV infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2647710